Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex |
| |
| Authors: | Deepika Appalla MD Andres Depalma MD Stanley Calderwood MD |
| |
| Institution: | 1. Division of Pediatric Hematology and Oncology, Department of Paediatrics, The Children's Hospital at Saint Peter's University Hospital, New Brunswick, New Jersey;2. University Radiology, Saint Peter's University Hospital, New Brunswick, New Jersey |
| |
| Abstract: | The majority of patients with subependymal giant cell astrocytoma (SEGA) have tuberous sclerosis complex (TSC). In such patients, the mammalian target of rapamycin (mTOR) inhibitor everolimus has been shown to induce responses. Isolated SEGA have been reported in patients without clinical or genetic features of TSC. The treatment of these patients with everolimus has not previously been reported. We treated a patient with a recurrent isolated SEGA with an mTOR inhibitor. The patient tolerated therapy well and had a sustained complete remission. MTOR inhibitors may be useful for the treatment of isolated SEGA. Further study is warranted. |
| |
| Keywords: | biological response modifier gliomas low grade rare tumors |
|
